Category Archives: Biotechnology

Where Does Arcus Biosciences Inc (RCUS) Stock Fall in the Biotechnology Field After It Is Lower By -12.07% This Week?  InvestorsObserver

Read more:
Where Does Arcus Biosciences Inc (RCUS) Stock Fall in the Biotechnology Field After It Is Lower By -12.07% This Week? - InvestorsObserver

Should Biotechnology Stock Design Therapeutics Inc (DSGN) Be in Your Portfolio Thursday?  InvestorsObserver

Read this article:
Should Biotechnology Stock Design Therapeutics Inc (DSGN) Be in Your Portfolio Thursday? - InvestorsObserver

Where Does Ardelyx Inc (ARDX) Stock Fall in the Biotechnology Field After It Is Up 4.65% This Week?  InvestorsObserver

Read the rest here:
Where Does Ardelyx Inc (ARDX) Stock Fall in the Biotechnology Field After It Is Up 4.65% This Week? - InvestorsObserver

Vaccination helped India's healthcare system's transition from reactive to proactive: biotechnology Secretary  Devdiscourse

View post:
Vaccination helped India's healthcare system's transition from reactive to proactive: biotechnology Secretary - Devdiscourse

Enjoy hands-on laboratory training and high-calibre foundational courses as you learn about scientific manipulation of living organisms. This program equips you with current scientific and technical expertise and the business and communication skills to start your biotechnology career as soon as you graduate.

You can combine your studies with full-time, paid work at top local and international organizations.

You can study intense specialization in a single field.

Biotechnology harnesses our scientific understanding of biology and chemistry to create products, processes, or services relevant to areas such as health, energy, agriculture, and the environment. Biotechnology applications include the design and production of vaccines, the discovery of new antibiotics, genetic engineering of tissues, the design of disease and drought resistant crops, and clean-up of environmental pollutants. The discipline uses computers to model biological structures and processes as well as analyze and compare DNA and RNA sequences. Some of the cutting-edge technologies employed in biotechnology include CRISPR Cas9 gene editing systems, mass spectrometry, and Next Generation DNA sequencing.

The Honours Bachelors of Biotechnology program is offered in cooperation with the BC Institute of Technology (BCIT). You must complete a 30-credit first-year program at UBC before transferring to BCIT for two years. Then you return to UBC for two years of academic and co-op work terms. The program spans a range of scientific disciplines including microbiology, immunology, virology, cell biology, plant biology, bioinformatics, chemistry, and statistics. The program also provides a solid foundation in business communications, accounting, and marketing.

Youll take courses in the new state-of-the-art Biosciences Teaching building, the flagship Life Sciences Centre, and the Michael Smith Laboratories, the latter of which is named after the Nobel laureate and UBC professor Dr. Michael Smith.

The Honours Biotechnology degree provides the best of two educational worlds: UBCs leading-edge biotechnology research and teaching, and BCITs hands-on laboratory training and foundational courses. Laboratory and lecture components of the program are uniquely integrated through the use of an experiential approach to learning.

Follow this link:
Biotechnology at UBC's Vancouver campus | Undergraduate Program and ...

How the Federal Government Regulates Biotech Plants

The Federal government has a coordinated, risk-based system to ensure that new biotechnology products are safe for the environment and human and animal health. Established as a formal policy in 1986, the Coordinated Framework for Regulation of Biotechnology (PDF, 479KB) describes the Federal system for evaluating products developed using modern biotechnology. The Coordinated Framework is based upon existing laws designed to protect public health and the environment. The U.S. government has written new regulations, policies, and guidance to apply these laws to biotechnology-derived products.

The U.S. Government agencies responsible for oversight of the products of agricultural modern biotechnology are the USDA's Animal and Plant Health Inspection Service (USDA-APHIS), the U.S. Environmental Protection Agency (EPA), and the Department of Health and Human Services' Food and Drug Administration (FDA). Depending on its characteristics, a product may be subject to the jurisdiction of one or more of these agencies. Regulatory officials from the three agencies regularly communicate and exchange information to ensure that any safety or regulatory issues that may arise are appropriately resolved.

Within USDA, the Animal and Plant Health Inspection Service (APHIS) is responsible for protecting agriculture from pests and diseases. Under the Plant Protection Act, USDA-APHIS has regulatory oversight over products of modern biotechnology that could pose such a risk. Accordingly, USDA-APHIS regulates organisms and products that are known or suspected to be plant pests or to pose a plant pest risk, including those that have been altered or produced through genetic engineering. These are called "regulated articles." USDA-APHIS regulates the import, handling, interstate movement, and release into the environment of regulated organisms that are products of biotechnology, including organisms undergoing confined experimental use or field trials. Regulated articles are reviewed to ensure that, under the proposed conditions of use, they do not present a plant pest risk through ensuring appropriate handling, confinement and disposal.

USDA-APHIS regulations provide a petition process for the determination of non regulated status. If a petition is granted, that organism will no longer be considered a "regulated article" and will no longer be subject to oversight by USDA-APHIS. The petitioner must supply information such as the biology of the recipient plant, experimental data and publications, genotypic and phenotypic descriptions of the genetically engineered organism, and field test reports. The agency evaluates a variety of issues including the potential for plant pest risk; disease and pest susceptibilities; the expression of gene products, new enzymes, or changes to plant metabolism; weediness and impact on sexually compatible plants; agricultural or cultivation practices; effects on non-target organisms; and the potential for gene transfer to other types of organisms. A notice is filed in the Federal Register and public comments are considered on the environmental assessment and determination written for the decision on granting the petition. Copies of the USDA-APHIS documents are available to the public.

For more information, visit: http://www.aphis.usda.gov/aphis/ourfocus/biotechnology

The EPA through a registration process regulates the sale, distribution and use of pesticides in order to protect health, and the environment, regardless of how the pesticide was made or its mode of action. This includes regulation of those pesticides that are produced by an organism through techniques of modern biotechnology. The Biopesticides and Pollution Prevention Division of the Office of Pesticide Programs, under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), regulates the distribution, sale, use and testing of pesticidal substances produced in plants and microbes. Generally, Experimental Use Permits are issued for field testing. Applicants must register pesticidal products prior to their sale and distribution, and the EPA may establish conditions for use as part of the registration. The EPA also sets tolerance limits for residues of pesticides on and in food and animal feed, or establishes an exemption from the requirement for a tolerance, under the Federal Food, Drug and Cosmetic Act.

For more information, visit: http://www.epa.gov/pesticides/biopesticides

The FDA is responsible for ensuring the safety and proper labeling of all plant-derived food and feed, including those developed through genetic engineering. All food and feed, whether imported or domestic and whether derived from crops modified by conventional breeding techniques or by genetic engineering techniques, must meet the same rigorous safety standards. Under the Federal Food, Drug, and Cosmetic Act, it is the responsibility of food and feed manufacturers to ensure that the products they market are safe and properly labeled. In addition, any food additive, including one introduced into food or feed by way of plant breeding, must receive FDA approval before marketing. (The term "food additive" refers to substances introduced into food that are not pesticides and are not generally recognized as safe by qualified scientific experts.)

The FDA ensures that food and feed manufacturers meet their obligations through its enforcement authority under the Federal Food, Drug, and Cosmetic Act. To help sponsors of food and feed derived from genetically engineered crops meet their legal obligations, the FDA encourages manufacturers to participate in its voluntary consultation process. Developers routinely consult with FDA prior to marketing. The goal of the consultation process is to ensure that human food and animal feed safety issues or other regulatory issues are resolved prior to commercial distribution.

For more information, visit: http://www.fda.gov/Food/IngredientsPackagingLabeling/GEPlants/default.htm

Read the rest here:
Regulation of Biotech Plants | USDA

1. Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies  GeekWire
2. Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization  Yahoo Finance
3. Sana Biotechnology to lay off 15% of its employees - Puget Sound Business Journal  The Business Journals
4. Sana Biotechnology Outlines Pipeline Prioritization, Reduces Workforce - Sana Biotechnology (NASDAQ:SANA)  Benzinga
5. Sana Biotechnology to cut 15% of workforce, shift pipeline - San Francisco Business Times  The Business Journals
6. View Full Coverage on Google News

Read more:
Sana Biotechnology will cut 15% of its workforce in latest layoffs affecting Seattle companies - GeekWire

VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (Sirona) is pleased to announce it has entered into a research collaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to advance Sironas antiviral library of compounds.

ICGEB will immediately begin screening the library of compounds produced at Sironas subsidiary TFChem. The work will be performed at the ICGEBs Laboratory of Molecular Virology located in Trieste, Italy under the direction of Dr Alessandro Marcello, an expert in human virology. Scientists at ICGEB will test the potential antivirals against SARS-CoV-2 (COVID-19) using specialized assays developed at the centre. Previous assays on Sironas compounds (performed at another institution) delivered inconclusive results that prevented the company from assessing the value of the suite of compounds. To address this problem, TFChem initiated a collaboration with Dr Marcellos team at the ICGEB. The testing in his laboratory is ideally suited for this class of antiviral agents and will provide data required to assess the potential of this program.

If the results are promising, it is the intention of the parties to expand the collaboration to further advance these compounds. Ultimately the collective goal is to create new treatment options for SARS-CoV-2 and other viruses. Sironas scientists at TFChem require the added expertise in virology to advance this project and this collaboration is a critical step for this program. An enormous unmet need remains in finding better therapies to treat SARS-CoV-2 and numerous other related viruses.

This initial evaluation is estimated to be completed in approximately 12 weeks. An update will be provided after the tests have been performed and the results have been evaluated.

About the International Centre for Genetic Engineering and Biotechnology

Established in 1983 as a special project of UNIDO, the International Centre for Genetic Engineering and Biotechnology - ICGEB is an independent intergovernmental organization with HQ in Trieste (Italy) and with additional laboratories in New Delhi (India) and Cape Town (South Africa). It counts almost 70 Member States. The ICGEB is a not for profit IGO any revenues generated are re-invested in research and in the funding programs for capacity building in its Member States. The Vision of the ICGEB is to be the worlds leading intergovernmental Organization for research, training and technology transfer in the field of Life Sciences and Biotechnology. Its Mission is to combine scientific research with capacity enhancement, thereby promoting sustainable global development (www.icgeb.org).

The Molecular Virology Group in Trieste studies the detection and molecular mechanisms of different arboviruses and has been mainly involved in the response to the COVID-19 pandemic providing support to the ICGEB Member countries. Activities included in the formulation for protocols for SARS-CoV-2 molecular and serological diagnostics, online tutorials and reagents to be able to develop low-cost in-house assays. COVID-19 viruses circulating in several countries have been sequenced for the first time and made available to the scientific community. A pipeline for testing antivirals against SARS-CoV-2 has been set-up allowing the identification of novel drug candidates.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sironas compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sironas laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit http://www.sironabiochem.com.

For more information regarding this press release, please contact:

Investor Enquiries:Jonathan WilliamsManaging DirectorMomentum PRPhone: 1.450.332.6939Email: jwilliams@momentumpr.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

---------------------------------------------

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochems forward-looking statements due to the risks and uncertainties inherent in Sirona Biochems business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

Read the original post:
Sirona Biochem Signs Research Collaboration Agreement with

Clal Biotechnology Industries Third Quarter 2022 Earnings: 0.015 loss per share (vs 0.12 loss in 3Q 2021)  Simply Wall St

Excerpt from:
Clal Biotechnology Industries Third Quarter 2022 Earnings: 0.015 loss per share (vs 0.12 loss in 3Q 2021) - Simply Wall St

Is Ocugen Inc (OCGN) Stock at the Top of the Biotechnology Industry?  InvestorsObserver

Continue reading here:
Is Ocugen Inc (OCGN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver